

## SUPPLEMENTARY MATERIAL

### *Clinical Drug Investigation*

#### **Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Coadministered With Acetaminophen or Naproxen: A Randomized Trial**

Ramesh Boinpally<sup>1</sup>, John Spaventa<sup>1</sup>, Kayla Chen<sup>2</sup>, Matthew Butler<sup>3</sup>

<sup>1</sup>Clinical Pharmacology, AbbVie, Madison, NJ, USA; <sup>2</sup>Data & Statistical Sciences, AbbVie, Madison, NJ, USA; <sup>3</sup>Global Patient Safety & Epidemiology, AbbVie, Madison, NJ, USA

#### **Corresponding Author:**

Ramesh Boinpally, PhD

Ramesh.Boinpally@AbbVie.com

**Table S1. Intervention Sequences**

Sequence	Period 1	Period 2	Period 3	Period 4	Period 5
I	A	B	E	C	D
II	B	C	A	D	E
III	C	D	B	E	A
IV	D	E	C	A	B
V	E	A	D	B	C
VI	D	C	E	B	A
VII	E	D	A	C	B
VIII	A	E	B	D	C
IX	B	A	C	E	D
X	C	B	D	A	E

Intervention A: Single dose of 60 mg atogepant.

Intervention B: Single dose of 1000 mg acetaminophen.

Intervention C: Coadministration of 60 mg atogepant and 1000 mg acetaminophen.

Intervention D: Single dose of 500 mg naproxen.

Intervention E: Coadministration of 60 mg atogepant and 500 mg naproxen.